In the Margins
French pharmaceutical company Sanofi said it will seek to replace the board of Medivation after the American drug maker’s directors rejected a $9.3 billion takeover offer. Sanofi said in April that Medivation’s directors had failed to respond to its approach. Meanwhile, Medivation’s board called the offer “inadequate,” and founder and CEO David Hung has said the French company’s move was “opportunistically timed.” Read the original story from The New York Times.
Most Read
Average compensation among mutual fund independent directors was higher in 2024, when compared to the year prior, an increase that was more than double what their ...
Comprehensive guidance on the oversight of sub-advisers that exists in the market has served mutual fund boards well for over 15 years. These frameworks remain foundational, ...
Independent directors who anticipate overseeing exchange-traded fund share classes are contemplating myriad issues related to what many industry participants believe will be a seismic shift in ...
Over the past several weeks, I have written articles exploring conflicts of interest that could challenge a variety of financial industry participants. Those articles explored potential ...